Dimension Therapeutics

About:

Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.

Twitter/X: dimensiontx

Top Investors: OrbiMed, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Rock Springs Capital

Description:

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Total Funding Amount:

$125M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)dimensiontx.com

Founders:

Allan M. Fox, Ben Auspitz, Kenneth T. Mills

Number of Employees:

51-100

Last Funding Date:

2015-04-21

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai